Adju-Phos® adjuvant
Aluminium phosphate wet gel
Catalog code: vac-phos-250
https://www.invivogen.com/adju-phos

Distributed by InvivoGen for research use only.
Version 20J08-MM

PRODUCT INFORMATION

Contents
• 250 ml of Adju-Phos® adjuvant provided as a ready-to-use, aluminium phosphate wet gel (colloidal) suspension. It is sterilized by autoclaving and aseptically filled.

Storage and stability
• Adju-Phos® adjuvant is shipped at room temperature and should be stored at room temperature. The expiry date is specified on the product label. The product tolerates re-autoclaving but is destroyed if frozen. DO NOT FREEZE.

Quality control
• Adju-Phos® adjuvant has been tested for pyrogenicity and sterility.
• The pH at the time of production has been confirmed.

DESCRIPTION

Adju-Phos® adjuvant is an aluminium phosphate wet gel suspension. Aluminium adjuvants, comprising Adju-Phos® and Alhydrogel® (aluminium hydroxide), are the most commonly used class of adjuvants. Both products increase Th2 antibodies but do not promote significant Th1 cellular responses. These adjuvants improve attraction and uptake of antigen by antigen presenting cells (APCs). It has been suggested that the antigens adsorbed on the aluminium salts are presented in a particulate form, making them more efficiently internalized by APCs. The main difference between the two aluminium salts is their point of zero charge (PZC), the pH value at which the surface of the adjuvant has a net neutral charge. The PZC influences the adjuvant’s ability to adsorb and release antigen.

For example, when the pH is maintained at 6-8, which is normal during vaccine production, Adju-Phos® particles have a negative electrical charge and thus are well suited for adsorption of positively charged antigens (e.g. antigens with isoelectric points above the pH of formulation). In contrast, neutral pH Alhydrogel® particles are positively charged and thus readily adsorb negatively charged antigens. Several other factors significantly change the adsorption capacity of both Alhydrogel® and Adju-Phos®, including molecular weight of protein antigens, sodium chloride, phosphate buffer, denaturing agents, and size of aluminium particles. The adsorption capacity for a model protein such as IgG or lysozyme in Adju-Phos® varies from 0.4 to 0.6 (mg/mg Al). Another difference between these two salts is that following injection, Adju-Phos® adjuvant dissolves by Croda (following its acquisition of Brenntag Biosector A/S), a leader in the global vaccine adjuvants market with a long history of producing high quality products. Aluminium phosphate adjuvants are commonly used in diptheria, tetanus, pertussis (DTP), hepatitis B (HBV), Polio and Haemophilus influenza type B (HIB) vaccines. Adju-Phos® adjuvant is used in multiple commercial vaccine formulations.

CHEmICAL PROPERTIES

CAS Number: 7784-30-7
Formulation: Al(OH)₃(PO₄)₂ Amorphous aluminium hydroxyphosphate
Appearance: White gelatinous precipitate
Aluminium content: 0.45%-0.55% w/w
pH: 6.0-7.0 (at the time of production)

METHODS

Preparation of antigen-Adju-Phos® adjuvant mixture
Antigens are preferentially diluted in saline or phosphate buffers. The amount of protein or conjugated peptide used for the primary immunization can be adjusted depending upon availability and immunogenicity of the antigen. The adsorption capacity for a model protein such as IgG or lysozyme in Adju-Phos® varies from 0.4 to 0.6 (mg/mg Al): 1. Shake vigorously before use the capped bottle of Adju-Phos® adjuvant. 2. Add Adju-Phos® adjuvant to the antigen solution; the final volume ratio of Adju-Phos® adjuvant to antigen should range from 1:1 (100 μl Adju-Phos® adjuvant for 100 μl of antigen) to 1:9 (100 μl Adju-Phos® adjuvant for 900 μl of antigen). 3. Mix well by pipetting up and down for at least 5 minutes to allow Adju-Phos® adjuvant to effectively adsorb the antigen.

The volume of injection depends on the site of administration. For example, 100 μl can be injected subcutaneously in mice. Note: To avoid lung embolism or anaphylaxis, do not use adjuvants for intravenous injection.

RELATED PRODUCTS

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Catalog Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alum and emulsions</td>
<td>Squalene-o/w</td>
<td>vac-adx-10</td>
</tr>
<tr>
<td>Alhydrogel® adjuvant 2% CFA</td>
<td>Al(OH)₃ gel</td>
<td>vac-alu-250</td>
</tr>
<tr>
<td>PRR ligands</td>
<td>Complete Freund’s Adjuvant</td>
<td>vac-cfa-10</td>
</tr>
<tr>
<td>2’3’-cGAMP VacciGrade™</td>
<td>STING agonist</td>
<td>vac-narc23</td>
</tr>
<tr>
<td>MPLA VacciGrade™</td>
<td>TLR4 agonist</td>
<td>vac-mpla</td>
</tr>
<tr>
<td>ODN 1826 VacciGrade™</td>
<td>Murine TLR9 agonist</td>
<td>vac-1826-1</td>
</tr>
<tr>
<td>Poly(I:C) VacciGrade™</td>
<td>TLR3 agonist</td>
<td>vac-pic</td>
</tr>
<tr>
<td>R848 VacciGrade™</td>
<td>TLR7/8 agonist</td>
<td>vac-r848</td>
</tr>
<tr>
<td>OVA Antigens</td>
<td>For in vivo use</td>
<td>vac-pova</td>
</tr>
<tr>
<td>EnfFit® Ovalbumin</td>
<td>For detection; ELISPOT</td>
<td>vac-sin</td>
</tr>
<tr>
<td>Ova 257-264</td>
<td>For detection; ELISPOT</td>
<td>vac-isq</td>
</tr>
<tr>
<td>Ova 323-339</td>
<td>For detection; ELISPOT</td>
<td>vac-isq</td>
</tr>
</tbody>
</table>

For a complete list of adjuvants provided by InvivoGen, please visit https://www.invivogen.com/vaccine-adjuvants.

Adju-Phos® is a trademark of Croda.

REFERENCES

4. Powell B. et al., 2015.
5. Lindblad EB. et al., 2016.

TECHNICAL SUPPORT
InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Hong Kong: +852 3622-34-80
E-mail: info@invivogen.com